ATE482946T1
(de)
*
|
1999-02-10 |
2010-10-15 |
Astrazeneca Ab |
Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
|
MXPA02004366A
(es)
|
1999-11-05 |
2002-11-07 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores vegf.
|
AU2001235804A1
(en)
|
2000-03-06 |
2001-09-17 |
Astrazeneca Ab |
Therapy
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
BR0113358A
(pt)
*
|
2000-08-21 |
2003-07-01 |
Astrazeneca Ab |
Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
|
JP2004511479A
(ja)
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2282299T3
(es)
|
2000-10-20 |
2007-10-16 |
EISAI R&D MANAGEMENT CO., LTD. |
Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos.
|
ATE502928T1
(de)
|
2000-11-01 |
2011-04-15 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
HU230574B1
(hu)
|
2000-12-21 |
2023-11-28 |
Novartis Ag |
Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
|
US6995162B2
(en)
*
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
*
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
HN2002000067A
(es)
*
|
2001-03-23 |
2003-10-24 |
Bayer Healthcare Llc |
Inhibidores de la rho - quinasa.
|
TWI336328B
(en)
*
|
2001-03-23 |
2011-01-21 |
Bayer Healthcare Llc |
Rho-kinase inhibitors
|
WO2002085895A1
(en)
*
|
2001-04-19 |
2002-10-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
US7501516B2
(en)
*
|
2001-07-16 |
2009-03-10 |
Astrazeneca Ab |
Quinoline derivatives and their use as tyrosine kinase inhibitors
|
GB0128109D0
(en)
*
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
EP1474420B1
(en)
*
|
2002-02-01 |
2012-03-14 |
AstraZeneca AB |
Quinazoline compounds
|
WO2003066602A1
(fr)
|
2002-02-06 |
2003-08-14 |
Ube Industries, Ltd. |
Procede relatif a l'elaboration d'un compose 4-aminoquinazoline
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE60327323D1
(de)
*
|
2002-07-09 |
2009-06-04 |
Astrazeneca Ab |
Chinazoline derivative und ihre anwendung in der krebsbehandlung
|
EP1521747B1
(en)
|
2002-07-15 |
2018-09-05 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
WO2004018430A1
(ja)
*
|
2002-08-23 |
2004-03-04 |
Kirin Beer Kabushiki Kaisha |
TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
|
SI1562955T1
(sl)
|
2002-11-04 |
2008-06-30 |
Astrazeneca Ab |
Derivati kinazolina kot inhibitorji Src-triozin kinaze
|
JPWO2004080462A1
(ja)
|
2003-03-10 |
2006-06-08 |
エーザイ株式会社 |
c−Kitキナーゼ阻害剤
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0310401D0
(en)
*
|
2003-05-07 |
2003-06-11 |
Astrazeneca Ab |
Therapeutic agent
|
GB0316127D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0316123D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
GB0318422D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
CN102432552B
(zh)
*
|
2003-08-14 |
2016-01-20 |
阿雷生物药品公司 |
作为受体酪氨酸激酶抑制剂的喹唑啉类似物
|
CA2537812C
(en)
|
2003-09-26 |
2013-01-22 |
Exelixis, Inc. |
C-met modulators and method of use
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
GB0328040D0
(en)
*
|
2003-12-03 |
2004-01-07 |
Coleman Robert E |
Pharmaceutical uses of bisphosphonates
|
SG141459A1
(en)
|
2003-12-23 |
2008-04-28 |
Pfizer |
Novel quinoline derivatives
|
GB0330002D0
(en)
*
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GEP20084439B
(en)
*
|
2004-01-23 |
2008-07-25 |
Amgen Inc |
Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
|
EP1711495A2
(en)
*
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
GB0406445D0
(en)
*
|
2004-03-23 |
2004-04-28 |
Astrazeneca Ab |
Combination therapy
|
GB0406446D0
(en)
*
|
2004-03-23 |
2004-04-28 |
Astrazeneca Ab |
Combination therapy
|
MXPA06010755A
(es)
*
|
2004-03-23 |
2006-12-15 |
Astrazeneca Ab |
Terapia de combinacion.
|
JP5097539B2
(ja)
|
2004-05-07 |
2012-12-12 |
アムジエン・インコーポレーテツド |
タンパク質キナーゼ調節剤および使用方法
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
EP2364699A1
(en)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Joint use of sulfonamide based compound with angiogenesis inhibitor
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
TW200624431A
(en)
|
2004-09-24 |
2006-07-16 |
Hoffmann La Roche |
Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
|
CA2579067A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Astrazeneca Ab |
Cancer combination therapy comprising azd2171 and imatinib
|
MX2007004403A
(es)
|
2004-10-12 |
2007-04-27 |
Astrazeneca Ab |
Derivados de quinazolina.
|
CA2587642C
(en)
|
2004-11-30 |
2013-04-09 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
EP1674467A1
(en)
*
|
2004-12-22 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
|
KR20070113286A
(ko)
|
2005-04-14 |
2007-11-28 |
에프. 호프만-라 로슈 아게 |
아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
ES2333182T3
(es)
|
2005-05-18 |
2010-02-17 |
Array Biopharma, Inc. |
Derivados de 4-(fenilamino)-6-oxo-1,6-dihidropiridazina-3-carboxamida como inhibidores de mek para el tratamiento de enfermedades hiperproliferativas.
|
AU2006265835B2
(en)
|
2005-06-30 |
2012-05-03 |
Amgen Inc. |
Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
|
EP1925941B1
(en)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
EP1938842A4
(en)
*
|
2005-09-01 |
2013-01-09 |
Eisai R&D Man Co Ltd |
METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
|
US8247556B2
(en)
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
CN101316590B
(zh)
|
2005-11-07 |
2011-08-03 |
卫材R&D管理有限公司 |
血管生成抑制剂和c-kit激酶抑制剂的组合使用
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
GB0523810D0
(en)
*
|
2005-11-23 |
2006-01-04 |
Astrazeneca Ab |
Pharmaceutical compositions
|
PT1965801E
(pt)
*
|
2005-12-22 |
2011-05-25 |
Astrazeneca Ab |
Combina??o de azd2171 e pemetrexed
|
US7868177B2
(en)
|
2006-02-24 |
2011-01-11 |
Amgen Inc. |
Multi-cyclic compounds and method of use
|
EP1991531A1
(en)
*
|
2006-02-28 |
2008-11-19 |
Amgen Inc. |
Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
|
JP2009528336A
(ja)
*
|
2006-03-02 |
2009-08-06 |
アストラゼネカ アクチボラグ |
キノリン誘導体
|
UY30183A1
(es)
*
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
RU2448708C3
(ru)
*
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
SI2057156T1
(sl)
*
|
2006-08-23 |
2017-06-30 |
Kudos Pharmaceuticals Limited |
Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
|
JP5368096B2
(ja)
|
2006-08-28 |
2013-12-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
未分化型胃癌に対する抗腫瘍剤
|
US7977347B2
(en)
|
2006-09-11 |
2011-07-12 |
Curis, Inc. |
Quinazoline based EGFR inhibitors
|
AU2012204077B2
(en)
*
|
2006-11-02 |
2012-11-29 |
Astrazeneca Ab |
Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
|
US7851623B2
(en)
*
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
AU2007338793B2
(en)
|
2006-12-20 |
2012-05-03 |
Amgen Inc. |
Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
US8148532B2
(en)
|
2007-03-14 |
2012-04-03 |
Guoqing Paul Chen |
Spiro substituted compounds as angiogenesis inhibitors
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
EP2134340A1
(en)
*
|
2007-04-13 |
2009-12-23 |
AstraZeneca AB |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
TWI484960B
(zh)
|
2007-04-16 |
2015-05-21 |
Hutchison Medipharma Entpr Ltd |
嘧啶衍生物
|
WO2009030224A2
(de)
*
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
AU2008299896B2
(en)
|
2007-09-10 |
2012-02-02 |
Curis, Inc. |
Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
TW200922590A
(en)
*
|
2007-09-10 |
2009-06-01 |
Curis Inc |
VEGFR inhibitors containing a zinc binding moiety
|
US8119616B2
(en)
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
AU2008309383B2
(en)
|
2007-10-11 |
2012-04-19 |
Astrazeneca Ab |
Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
|
US7795254B2
(en)
*
|
2007-10-29 |
2010-09-14 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
PE20131210A1
(es)
|
2007-12-19 |
2013-10-31 |
Genentech Inc |
Derivados de 5-anilinoimidazopiridina como inhibidores de mek
|
CA2708176A1
(en)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines and methods of use
|
CN101215274B
(zh)
*
|
2007-12-27 |
2011-05-04 |
上海北卡医药技术有限公司 |
N取代吗啉类有机化合物的制备工艺
|
JP5529757B2
(ja)
*
|
2008-01-17 |
2014-06-25 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
免疫調節薬としてのスルホキシミン置換キナゾリン誘導体、それらの調製及び医薬品としての使用
|
WO2009094211A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Quinazoline compounds and methods of treating cancer
|
US20100324087A1
(en)
*
|
2008-01-29 |
2010-12-23 |
Eisai R&D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
PL2245026T3
(pl)
|
2008-02-07 |
2013-01-31 |
Boehringer Ingelheim Int |
Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
|
CA2715181A1
(en)
*
|
2008-02-21 |
2009-08-27 |
Astrazeneca Ab |
Combination therapy 238
|
RU2509558C2
(ru)
*
|
2008-03-26 |
2014-03-20 |
Новартис Аг |
Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов
|
US7829574B2
(en)
*
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
ES2444128T3
(es)
|
2008-05-13 |
2014-02-24 |
Astrazeneca Ab |
Nueva SAL-554
|
US8426430B2
(en)
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
EP2149565A1
(de)
|
2008-07-24 |
2010-02-03 |
Bayer Schering Pharma AG |
Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
US8211911B2
(en)
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
US7737157B2
(en)
|
2008-08-29 |
2010-06-15 |
Hutchison Medipharma Enterprises Limited |
Pyrimidine compounds
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
WO2010045095A1
(en)
|
2008-10-14 |
2010-04-22 |
Ning Xi |
Compounds and methods of use
|
US20110053923A1
(en)
|
2008-12-22 |
2011-03-03 |
Astrazeneca |
Chemical compounds 610
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
CA2995880C
(en)
|
2009-01-16 |
2021-01-05 |
Exelixis, Inc. |
Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
EP3100745B1
(en)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
WO2010092371A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
WO2010103094A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
IT1393351B1
(it)
*
|
2009-03-16 |
2012-04-20 |
Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa |
Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
|
AU2010229147B2
(en)
*
|
2009-03-21 |
2012-07-05 |
Sunshine Lake Pharma Co., Ltd. |
Amino ester derivatives, salts thereof and methods of use
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
CA2771675A1
(en)
|
2009-09-11 |
2011-03-17 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
CN102666545B
(zh)
|
2009-10-20 |
2016-04-06 |
塞尔卓姆有限公司 |
作为jak抑制剂的杂环吡唑并嘧啶类似物
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
RU2542582C2
(ru)
|
2009-11-18 |
2015-02-20 |
Астразенека Аб |
Производные бензимидазола, полезные при лечении состояний, ассоциированных с активностью р2х3 или р2х2/3
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
US9180127B2
(en)
*
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
AU2011206864B2
(en)
|
2010-01-15 |
2013-12-19 |
Suzhou Neupharma Co., Ltd. |
Certain chemical entities, compositions, and methods
|
CA2786520A1
(en)
|
2010-01-19 |
2011-07-28 |
Astrazeneca Ab |
Pyrazine derivatives
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
ES2535116T3
(es)
|
2010-03-04 |
2015-05-05 |
Cellzome Limited |
Derivados de urea sustituida con morfolino como inhibidores de mtor
|
JP2013525392A
(ja)
|
2010-04-30 |
2013-06-20 |
セルゾーム リミティッド |
Jak阻害剤としてのピラゾール化合物
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
JP2013534233A
(ja)
|
2010-08-20 |
2013-09-02 |
セルゾーム リミティッド |
選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
CA2815330A1
(en)
|
2010-11-09 |
2012-05-18 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as tyk2 inhibitors
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
JP2013542916A
(ja)
|
2010-11-19 |
2013-11-28 |
大日本住友製薬株式会社 |
環状アミド化合物および疾患の処置におけるその使用
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
US9493503B2
(en)
|
2011-02-02 |
2016-11-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
MY183977A
(en)
|
2011-02-15 |
2021-03-17 |
Immunogen Inc |
Cytotoxic benzodiazepine derivatives
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
JP5937111B2
(ja)
|
2011-02-17 |
2016-06-22 |
カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited |
Fak阻害剤
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US20140163023A1
(en)
|
2011-04-04 |
2014-06-12 |
Cellzome Limited |
Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
ES2841809T3
(es)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
EP3686193B1
(en)
|
2011-07-27 |
2022-03-02 |
Astrazeneca AB |
2-(2,4,5-substituted-anilino)pyrimidine compounds
|
AU2012288892B2
(en)
|
2011-07-28 |
2016-04-21 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as JAK inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
CN104053442B
(zh)
|
2011-08-26 |
2017-06-23 |
润新生物公司 |
某些化学实体、组合物及方法
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
JP6093768B2
(ja)
|
2011-09-14 |
2017-03-08 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
EP2760863A1
(en)
|
2011-09-20 |
2014-08-06 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
|
AU2012311458B2
(en)
|
2011-09-21 |
2016-02-04 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
EP2760458B1
(en)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9242993B2
(en)
|
2011-10-07 |
2016-01-26 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CN104169272A
(zh)
|
2011-12-23 |
2014-11-26 |
赛尔佐姆有限公司 |
作为激酶抑制剂的嘧啶-2,4-二胺衍生物
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
US9676813B2
(en)
|
2012-04-29 |
2017-06-13 |
Neupharma, Inc. |
Certain steroids and methods for using the same in the treatment of cancer
|
EP3505534A1
(en)
|
2012-06-08 |
2019-07-03 |
Sutro Biopharma, Inc. |
Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
CA2882158A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
WO2014047648A1
(en)
|
2012-09-24 |
2014-03-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RU2674249C2
(ru)
|
2012-11-05 |
2018-12-06 |
НэнтБайо, Инк. |
Замещенные производные индол-5-ола и их терапевтическое применение
|
EP2916838B1
(en)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
CN105246888B
(zh)
|
2013-01-31 |
2017-09-05 |
尼奥迈德研究所 |
咪唑并吡啶化合物及其用途
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
WO2015066584A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
ES2831625T3
(es)
*
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
WO2014134486A2
(en)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP4019491A1
(en)
|
2013-03-13 |
2022-06-29 |
AbbVie Ireland Unlimited Company |
Process for preparing a synthetic intermediate useful in the preparation of an apoptosis-inducing agent
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
CN105377261B
(zh)
|
2013-03-15 |
2017-12-15 |
南特生物科学公司 |
取代的吲哚‑5‑酚衍生物和它们的治疗应用
|
US9540381B2
(en)
*
|
2013-04-09 |
2017-01-10 |
Guangzhou Kangrui Biological Pharmaceutical Technology Co., Ltd. |
Anti-angiogenesis compound, intermediate and use thereof
|
AU2014266223B2
(en)
|
2013-05-14 |
2020-06-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
EP2806480B1
(en)
*
|
2013-05-20 |
2017-08-09 |
Nintendo Co., Ltd. |
Battery accomodation structure and battery accomodation method
|
CN103275069B
(zh)
*
|
2013-05-22 |
2015-03-11 |
苏州明锐医药科技有限公司 |
西地尼布的制备方法
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP3004073A1
(en)
|
2013-06-07 |
2016-04-13 |
Université catholique de Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
SG11201601138PA
(en)
|
2013-08-23 |
2016-03-30 |
Neupharma Inc |
Certain chemical entities, compositions, and methods
|
CN103509005B
(zh)
*
|
2013-09-26 |
2015-04-08 |
苏州海特比奥生物技术有限公司 |
喹唑啉类化合物及其制备方法与应用
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP2868702A1
(en)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Disperse dyes, their preparation and their use
|
JP6426194B2
(ja)
*
|
2013-11-01 |
2018-11-21 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物の結晶形態及びその使用
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
ES2926687T3
(es)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y método para su producción
|
CN105461698A
(zh)
*
|
2014-09-12 |
2016-04-06 |
杭州普晒医药科技有限公司 |
西地尼布盐及其晶型、以及其制备方法和药物组合物
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
AU2016220219B2
(en)
|
2015-02-17 |
2020-05-14 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
HUE064614T2
(hu)
|
2015-02-25 |
2024-04-28 |
Eisai R&D Man Co Ltd |
Eljárás egy kinolin-származék keserû ízének elnyomására
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
AU2016279474B2
(en)
|
2015-06-16 |
2021-09-09 |
Eisai R&D Management Co., Ltd. |
Anticancer agent
|
CA2994023A1
(en)
|
2015-08-04 |
2017-02-02 |
University Of South Australia |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
CN108473435A
(zh)
|
2015-10-05 |
2018-08-31 |
纽约市哥伦比亚大学理事会 |
自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
CN109073650A
(zh)
|
2016-02-15 |
2018-12-21 |
阿斯利康(瑞典)有限公司 |
包括对西地尼布进行固定的间歇给药的方法
|
WO2017178845A1
(en)
|
2016-04-15 |
2017-10-19 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
JP7101165B2
(ja)
|
2016-08-15 |
2022-07-14 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
EP3509422A4
(en)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
BR112019004463A2
(pt)
|
2016-09-08 |
2019-05-28 |
Kala Pharmaceuticals Inc |
formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
|
US10392399B2
(en)
|
2016-09-08 |
2019-08-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
EP3515903B1
(en)
|
2016-09-22 |
2020-10-21 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
JP6755775B2
(ja)
*
|
2016-11-04 |
2020-09-16 |
富士アミドケミカル株式会社 |
4−フルオロイソキノリンの製法
|
AU2017363307B2
(en)
|
2016-11-22 |
2021-07-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
|
US10287253B2
(en)
|
2016-12-05 |
2019-05-14 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
CN106831729A
(zh)
*
|
2016-12-19 |
2017-06-13 |
浙江工业大学 |
一种西地尼布的纯化方法
|
AU2018214431B2
(en)
|
2017-02-01 |
2021-07-29 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
EP4374858A2
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
EP3630749B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
CN111278840B
(zh)
|
2017-08-18 |
2023-11-17 |
癌症研究科技有限公司 |
吡咯并[2,3-b]吡啶化合物及其治疗癌症的用途
|
US20200353076A1
(en)
|
2017-09-18 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
CA3079673A1
(en)
*
|
2017-10-20 |
2019-04-25 |
Kala Pharmaceuticals, Inc. |
Ret9 and vegfr2 inhibitors
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
AU2019207517A1
(en)
|
2018-01-15 |
2020-08-27 |
Aucentra Therapeutics Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
AU2019218893A1
(en)
|
2018-02-08 |
2020-09-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
MX2020010805A
(es)
|
2018-04-13 |
2021-01-29 |
Cancer Research Tech Ltd |
Inhibidores de bcl6.
|
FR3080620B1
(fr)
|
2018-04-27 |
2021-11-12 |
Univ Paris Sud |
Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
|
CN112513031A
(zh)
|
2018-06-04 |
2021-03-16 |
阿普罗斯治疗公司 |
可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CN112996784B
(zh)
*
|
2018-09-18 |
2023-05-30 |
北京越之康泰生物医药科技有限公司 |
吲哚衍生物及其在医药上的应用
|
BR112021005513A2
(pt)
|
2018-09-25 |
2021-06-22 |
Black Diamond Therapeutics, Inc. |
derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
JP2022528562A
(ja)
|
2019-04-05 |
2022-06-14 |
ストーム・セラピューティクス・リミテッド |
Mettl3阻害化合物
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
CA3152674A1
(en)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivatives for fgfr inhibitor and preparation method thereof
|
MX2022003276A
(es)
|
2019-09-20 |
2022-04-11 |
Ideaya Biosciences Inc |
Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg.
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
CA3162166A1
(en)
|
2019-12-02 |
2021-06-10 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as mettl3 inhibitors
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
TW202306568A
(zh)
|
2021-05-17 |
2023-02-16 |
南韓商怡諾安有限公司 |
苯甲醯胺衍生物、包含其之醫藥組成物、包含其之健康功能食品組成物、包含其之組合製劑、及其用途
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
WO2023057389A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023161881A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024003241A1
(en)
|
2022-06-30 |
2024-01-04 |
Astrazeneca Ab |
Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024059169A1
(en)
*
|
2022-09-14 |
2024-03-21 |
Blueprint Medicines Corporation |
Egfr inhibitors
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|